Live quote temporarily unavailable — press releases and news are still shown below.

MYNZHealthcare

MYNZ

News

No News Yet

Press releases and SEC filings for MYNZ will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open—

Prev Close—

Day Range—

52W Range$0.55 – $5.34

Volume—

P/E (TTM)—

EPS$-5.28

Dividend Yield—

Beta0.32

Revenue Growth-44.90%

Analyst Ratings

Hold1 analysts

Buy 0Hold 1Sell 0

About

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

Healthcare · Diagnostics & Research

19 employees

mainzbiomed.com

Insider Trades (90d)

Net Shares

+820,000

Net $

—

4 trades · bought 820,000 / sold 0

Key People

BAECHLER GUIDO

Caragol William J

Donahue Kevin Michael